Trial · NCT05760430
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
NCT05760430, Phase 2, Unknown, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma. Trials, record NCT05760430. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05760430
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
- NCT number
- NCT05760430
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Hepatocellular Carcinoma
- Interventions
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- First posted
- 2023-03-08
- Last updated
- 2023-03-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Conversion rate | The time frame is from the first treatment to the last treatment, an average of 2 years. | The proportion of patients with unresectable hepatocellular carcinoma who have achieved surgical R0 resection after combined treatment. |
| Secondary | Objective response rate | The time frame is from the first treatment to the last treatment, an average of 2 years. | The proportion of hepatocellular carcinoma patients with complete and partial remission in all evaluable patients. |
| Secondary | Residual liver volume proliferation rate after hepatectomy | The time frame is from the first treatment to the last treatment, an average of 2 years. | The proportion of residual liver volume to the preoperative liver volume of the patient was measured by CT image. |
| Secondary | Progression-free survival | The time frame is from the first treatment to the last treatment, an average of 2 years. | The time from the first treatment to the first assessment of recurrence, metastasis or death. |
| Secondary | Time to progress | The time frame is from the first treatment to the last treatment, an average of 2 years. | The time from the first treatment to the first assessment of recurrence or metastasis. |
| Secondary | Overall survival | The time from the first treatment to death (up to 3 years). The last follow-up time is for the patients who lost the follow-up, and the end of the follow-up is for the patients who are still alive at the end of the study. | The time from the first treatment to death (up to 3 years). The last follow-up time is for the patients who lost the follow-up, and the end of the follow-up is for the patients who are still alive at the end of the study. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05760430
GET https://conductscience.org/api/trials/v1/NCT05760430/registered